{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:29:09Z","timestamp":1791347349843,"version":"4.3.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T00:00:00Z","timestamp":1370304000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>HIV infection, anti-tuberculosis and efavirenz therapy are associated with neuropsychological effects. We evaluated the influence of rifampicin cotreatment, efavirenz pharmacokinetics and pharmacogenetics on neuropsychiatric disorders in Ugandan HIV patients with or without tuberculosis coinfection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>197 treatment na\u00efve Ugandan HIV patients, of whom 138 were TB co-infected, enrolled prospectively and received efavirenz based HAART. TB-HIV confected patients received concomitant rifampicin based anti-TB therapy. Genotypes for<jats:italic>CYP2B6<\/jats:italic>(*<jats:italic>6<\/jats:italic>,<jats:italic>*11<\/jats:italic>),<jats:italic>CYP3A5<\/jats:italic>(<jats:italic>*3<\/jats:italic>,<jats:italic>*6<\/jats:italic>,<jats:italic>*7<\/jats:italic>), ABCB1 (c.3435C&gt;T and c.4036 A\/G rs3842),<jats:italic>CYP2A6<\/jats:italic>(*9, *17) and<jats:italic>NR1I3<\/jats:italic>rs3003596 T\/C were determined. Efavirenz plasma concentrations were serially quantified at 3rd day, 1st, 2nd, 4th, 6th, 8th and 12th weeks during therapy. Efavirenz neuropsychiatric symptoms were evaluated in terms of sleep disorders, hallucinations and cognitive effects at baseline, at two and twelve weeks of efavirenz treatment using a modified Mini Mental State Examination (MMSE) score.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the first twelve weeks of ART, 73.6% of the patients experienced at least one efavirenz related neuropsychiatric symptom. Commonest symptoms experienced were sleep disorders 60.5% (n=124) and hallucination 30.7% (n=63). Neuropsychiatric symptoms during HAART were significantly predicted by efavirenz plasma concentrations consistently. Rifampicin cotreatment reduced plasma efavirenz concentrations significantly only during the first week but not afterwards. There was no significant difference in the incidence of neuropsychiatric symptoms between patients receiving efavirenz with or without rifampicin cotreatment.<jats:italic>CYP2B6*6<\/jats:italic>and ABCB1 c.4036 A\/G genotype significantly predicted efavirenz concentrations. The tendency of<jats:italic>CYP2B6*6<\/jats:italic>genotype association with higher incidence of having vivid dream (p=0.05), insomnia (p=0.19) and tactile hallucination (p=0.09) was observed mainly at week-2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Efavirenz related neuropsychiatric symptoms are common among Ugandan HIV patients receiving ART and is mainly predicted by higher efavirenz plasma concentrations and<jats:italic>CYP2B6<\/jats:italic>genotype but not by rifampicin based anti-TB co-treatment.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2334-13-261","type":"journal-article","created":{"date-parts":[[2013,6,4]],"date-time":"2013-06-04T12:14:21Z","timestamp":1370348061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study"],"prefix":"10.1186","volume":"13","author":[{"given":"Jackson K","family":"Mukonzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alphonse","family":"Okwera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neoline","family":"Nakasujja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Luzze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deogratious","family":"Sebuwufu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Ogwal-Okeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Waako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars L","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,4]]},"reference":[{"key":"2468_CR1","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/ana.22053","volume":"67","author":"JC McArthur","year":"2010","unstructured":"McArthur JC, Steiner J, Sacktor N, Nath A: Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol. 2010, 67: 699-714.","journal-title":"Ann Neurol"},{"key":"2468_CR2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s13365-012-0120-3","volume":"18","author":"K Robertson","year":"2012","unstructured":"Robertson K, Liner J, Meeker RB: Antiretroviral neurotoxicity. J Neurovirol. 2012, 18: 388-399. 10.1007\/s13365-012-0120-3.","journal-title":"J Neurovirol"},{"key":"2468_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/archinternmed.2009.432","volume":"170","author":"L Elzi","year":"2010","unstructured":"Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M: Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med. 2010, 170: 57-65. 10.1001\/archinternmed.2009.432.","journal-title":"Arch Intern Med"},{"key":"2468_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1086\/650539","volume":"50","author":"JT Schouten","year":"2010","unstructured":"Schouten JT, Krambrink A, Ribaudo HJ, Kmack A, Webb N, Shikuma C, Kuritzkes DR, Gulick RM: Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis. 2010, 50: 787-791. 10.1086\/650539.","journal-title":"Clin Infect Dis"},{"key":"2468_CR5","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1089\/apc.2006.20.542","volume":"20","author":"DJ Ward","year":"2006","unstructured":"Ward DJ, Curtin JM: Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS. 2006, 20: 542-548. 10.1089\/apc.2006.20.542.","journal-title":"AIDS Patient Care STDS"},{"key":"2468_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1086\/314945","volume":"180","author":"KT Tashima","year":"1999","unstructured":"Tashima KT, Caliendo AM, Ahmad M, Gormley JM, Fiske WD, Brennan JM, Flanigan TP: Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis. 1999, 180: 862-864. 10.1086\/314945.","journal-title":"J Infect Dis"},{"key":"2468_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jac\/dkq434","volume":"66","author":"BM Best","year":"2011","unstructured":"Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB, Collier AC, Gelman BB, Mbeo G, McCutchan JA, et al: Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011, 66: 354-357. 10.1093\/jac\/dkq434.","journal-title":"J Antimicrob Chemother"},{"key":"2468_CR8","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s10461-011-9939-5","volume":"15","author":"CA Kenedi","year":"2011","unstructured":"Kenedi CA, Goforth HW: A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011, 15: 1803-1818. 10.1007\/s10461-011-9939-5.","journal-title":"AIDS Behav"},{"key":"2468_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.7326\/0003-4819-143-10-200511150-00008","volume":"143","author":"DB Clifford","year":"2005","unstructured":"Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM: Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005, 143: 714-721. 10.7326\/0003-4819-143-10-200511150-00008.","journal-title":"Ann Intern Med"},{"key":"2468_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1177\/1545109709343967","volume":"8","author":"A Jena","year":"2009","unstructured":"Jena A, Sachdeva RK, Sharma A, Wanchu A: Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care (Chic). 2009, 8: 318-322. 10.1177\/1545109709343967.","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"key":"2468_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1310\/3Q91-YT2D-BUT4-8HN6","volume":"3","author":"JA Perez-Molina","year":"2002","unstructured":"Perez-Molina JA: Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials. 2002, 3: 279-286. 10.1310\/3Q91-YT2D-BUT4-8HN6.","journal-title":"HIV Clin Trials"},{"key":"2468_CR12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1468-1293.2006.00419.x","volume":"7","author":"TA Rihs","year":"2006","unstructured":"Rihs TA, Begley K, Smith DE, Sarangapany J, Callaghan A, Kelly M, Post JJ, Gold J: Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med. 2006, 7: 544-548. 10.1111\/j.1468-1293.2006.00419.x.","journal-title":"HIV Med"},{"key":"2468_CR13","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1097\/QAD.0b013e328353b047","volume":"26","author":"A Scourfield","year":"2012","unstructured":"Scourfield A, Zheng J, Chinthapalli S, Waters L, Martin T, Mandalia S, Nelson M: Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS. 2012, 26: 1399-1401. 10.1097\/QAD.0b013e328353b047.","journal-title":"AIDS"},{"key":"2468_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1124\/jpet.103.049601","volume":"306","author":"BA Ward","year":"2003","unstructured":"Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z: The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003, 306: 287-300. 10.1124\/jpet.103.049601.","journal-title":"J Pharmacol Exp Ther"},{"key":"2468_CR15","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1124\/dmd.109.031393","volume":"38","author":"ET Ogburn","year":"2010","unstructured":"Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z: Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos. 2010, 38: 1218-1229. 10.1124\/dmd.109.031393.","journal-title":"Drug Metab Dispos"},{"key":"2468_CR16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/clpt.2010.172","volume":"88","author":"E Ngaimisi","year":"2010","unstructured":"Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, et al: Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther. 2010, 88: 676-684. 10.1038\/clpt.2010.172.","journal-title":"Clin Pharmacol Ther"},{"key":"2468_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1124\/pr.107.07109","volume":"60","author":"DS Miller","year":"2008","unstructured":"Miller DS, Bauer B, Hartz AM: Modulation of P-glycoprotein at the blood\u2013brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008, 60: 196-209. 10.1124\/pr.107.07109.","journal-title":"Pharmacol Rev"},{"key":"2468_CR18","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s11095-006-0279-5","volume":"23","author":"G Dirson","year":"2006","unstructured":"Dirson G, Fernandez C, Hindlet P, Roux F, German-Fattal M, Gimenez F, Farinotti R: Efavirenz does not interact with the ABCB1 transporter at the blood\u2013brain barrier. Pharm Res. 2006, 23: 1525-1532. 10.1007\/s11095-006-0279-5.","journal-title":"Pharm Res"},{"key":"2468_CR19","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/j.1365-2125.2009.03516.x","volume":"68","author":"JK Mukonzo","year":"2009","unstructured":"Mukonzo JK, Roshammar D, Waako P, Andersson M, Fukasawa T, Milani L, Svensson JO, Ogwal-Okeng J, Gustafsson LL, Aklillu E: A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol. 2009, 68: 690-699. 10.1111\/j.1365-2125.2009.03516.x.","journal-title":"Br J Clin Pharmacol"},{"key":"2468_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3389\/fgene.2012.00236","volume":"3","author":"M Swart","year":"2012","unstructured":"Swart M, Ren Y, Smith P, Dandara C: ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV\/AIDS Patients. Front Genet. 2012, 3: 236-","journal-title":"Front Genet"},{"key":"2468_CR21","volume-title":"PLoS One","author":"E Ngaimisi","year":"2013","unstructured":"Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel K, Janabi M, Aderaye G, et al: Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two Sub-Saharan African populations. PLoS One. 2013, 10.1371\/journal.pone.0067946."},{"key":"2468_CR22","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2217\/pgs.10.94","volume":"11","author":"L Elens","year":"2010","unstructured":"Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V: Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics. 2010, 11: 1223-1234. 10.2217\/pgs.10.94.","journal-title":"Pharmacogenomics"},{"key":"2468_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S0140-6736(02)07276-8","volume":"359","author":"J Fellay","year":"2002","unstructured":"Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002, 359: 30-36. 10.1016\/S0140-6736(02)07276-8.","journal-title":"Lancet"},{"key":"2468_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1124\/jpet.106.112136","volume":"320","author":"SR Faucette","year":"2007","unstructured":"Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, Wang H: Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2007, 320: 72-80.","journal-title":"J Pharmacol Exp Ther"},{"key":"2468_CR25","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1093\/jac\/dkr304","volume":"66","author":"A Habtewold","year":"2011","unstructured":"Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel KD, Ueda N, Worku A, Haefeli WE, Lindquist L, Aderaye G, et al: Long-term effect of efavirenz autoinduction on plasma\/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother. 2011, 66: 2350-2361. 10.1093\/jac\/dkr304.","journal-title":"J Antimicrob Chemother"},{"key":"2468_CR26","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1097\/QAD.0b013e3283319908","volume":"23","author":"A Kwara","year":"2009","unstructured":"Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH: CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS. 2009, 23: 2101-2106. 10.1097\/QAD.0b013e3283319908.","journal-title":"AIDS"},{"key":"2468_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/00126334-200112010-00015","volume":"28","author":"M Nunez","year":"2001","unstructured":"Nunez M, Gonzalez de Reqeuna D, Gallego L, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V: Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr. 2001, 28: 399-400.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2468_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","volume":"15","author":"C Marzolini","year":"2001","unstructured":"Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001, 15: 71-75. 10.1097\/00002030-200101050-00011.","journal-title":"AIDS"},{"issue":"Suppl 2","key":"2468_CR29","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1468-1293.2005.00293.x","volume":"6","author":"AL Pozniak","year":"2005","unstructured":"Pozniak AL, Miller RF, Lipman MC, Freedman AR, Ormerod LP, Johnson MA, Collins S, Lucas SB: BHIVA treatment guidelines for tuberculosis (TB)\/HIV infection 2005. HIV Med. 2005, 6 (Suppl 2): 62-83.","journal-title":"HIV Med"},{"key":"2468_CR30","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","volume":"41","author":"LF Lopez-Cortes","year":"2002","unstructured":"Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, Leon-Jimenez E, Sarasanacenta M, Lopez-Pua Y, Pachon J: Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002, 41: 681-690. 10.2165\/00003088-200241090-00004.","journal-title":"Clin Pharmacokinet"},{"key":"2468_CR31","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1128\/AAC.00899-08","volume":"53","author":"G Ramachandran","year":"2009","unstructured":"Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, Narendran G, Menon P, Gomathi C, Swaminathan S: CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother. 2009, 53: 863-868. 10.1128\/AAC.00899-08.","journal-title":"Antimicrob Agents Chemother"},{"key":"2468_CR32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350901400502","volume":"14","author":"K Cohen","year":"2009","unstructured":"Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, Fielding K, Charalombous S, Churchyard G, Smith P, Maartens G: Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther. 2009, 14: 687-695.","journal-title":"Antivir Ther"},{"key":"2468_CR33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/clpt.2011.129","volume":"90","author":"E Ngaimisi","year":"2011","unstructured":"Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, et al: Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis. Clin Pharmacol Ther. 2011, 90: 406-413. 10.1038\/clpt.2011.129.","journal-title":"Clin Pharmacol Ther"},{"key":"2468_CR34","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1086\/497835","volume":"41","author":"F Gutierrez","year":"2005","unstructured":"Gutierrez F, Navarro A, Padilla S, Anton R, Masia M, Borras J, Martin-Hidalgo A: Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005, 41: 1648-1653. 10.1086\/497835.","journal-title":"Clin Infect Dis"},{"key":"2468_CR35","doi-asserted-by":"publisher","first-page":"655","DOI":"10.2165\/11534340-000000000-00000","volume":"24","author":"JS Kass","year":"2010","unstructured":"Kass JS, Shandera WX: Nervous system effects of antituberculosis therapy. CNS Drugs. 2010, 24: 655-667. 10.2165\/11534340-000000000-00000.","journal-title":"CNS Drugs"},{"key":"2468_CR36","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1176\/appi.psy.45.6.537","volume":"45","author":"RR Reeves","year":"2004","unstructured":"Reeves RR, Liberto V: Confusion associated with isoniazid-induced pyridoxine deficiency. Psychosomatics. 2004, 45: 537-538. 10.1176\/appi.psy.45.6.537.","journal-title":"Psychosomatics"},{"key":"2468_CR37","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1345\/aph.17377","volume":"32","author":"AO Alao","year":"1998","unstructured":"Alao AO, Yolles JC: Isoniazid-induced psychosis. Ann Pharmacother. 1998, 32: 889-891. 10.1345\/aph.17377.","journal-title":"Ann Pharmacother"},{"key":"2468_CR38","first-page":"54","volume":"44","author":"A Citak","year":"2002","unstructured":"Citak A, Kaya O, Ucsel R, Karabocuoglu M, Uzel N: Acute isoniazid neurotoxicity in childhood. Turk J Pediatr. 2002, 44: 54-57.","journal-title":"Turk J Pediatr"},{"key":"2468_CR39","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1097\/01.aids.0000183519.45137.a6","volume":"19","author":"P Brennan-Benson","year":"2005","unstructured":"Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D: Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS. 2005, 19: 1541-1543. 10.1097\/01.aids.0000183519.45137.a6.","journal-title":"AIDS"},{"key":"2468_CR40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","volume":"61","author":"D Burger","year":"2006","unstructured":"Burger D, van der Heiden I, La Porte C, van der Ende M, Groeneveld P, Richter C, Koopmans P, Kroon F, Sprenger H, Lindemans J, et al: Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006, 61: 148-154. 10.1111\/j.1365-2125.2005.02536.x.","journal-title":"Br J Clin Pharmacol"},{"key":"2468_CR41","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1093\/jac\/dkr272","volume":"66","author":"C Wyen","year":"2011","unstructured":"Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, et al: Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother. 2011, 66: 2092-2098. 10.1093\/jac\/dkr272.","journal-title":"J Antimicrob Chemother"},{"key":"2468_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1742-6405-7-32","volume":"7","author":"V Gounden","year":"2010","unstructured":"Gounden V, van Niekerk C, Snyman T, George JA: Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther. 2010, 7: 32-10.1186\/1742-6405-7-32.","journal-title":"AIDS Res Ther"},{"key":"2468_CR43","first-page":"99","volume":"102","author":"M Seydi","year":"2009","unstructured":"Seydi M, Diop SA, Dieng AB, Tekpa G, Soumare M, Diouf A, Niang K, Lakh A, Ndiaye I, Fall MB, et al: Tolerance study of a triple first-line antiretroviral combination zidovudine, lamivudine and efavirenz in Dakar, Senegal. Bull Soc Pathol Exot. 2009, 102: 99-100.","journal-title":"Bull Soc Pathol Exot"},{"key":"2468_CR44","first-page":"99","volume-title":"Pharmacogenomics in Admixed Populations","author":"E Aklillu","year":"2007","unstructured":"Aklillu E, Dandara C, Bertilsson L, Masimirembwa C: Pharmacogenetics of Cytochrome P450s in African Populations: Clinical and Molecular Evolutionary Implications. Pharmacogenomics in Admixed Populations. Edited by: Suarez-Kurtz G. 2007, Austin, TX: Landes Bioscience, 99-119."},{"key":"2468_CR45","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1093\/jac\/dkq369","volume":"65","author":"Y Jamshidi","year":"2010","unstructured":"Jamshidi Y, Moreton M, McKeown DA, Andrews S, Nithiyananthan T, Tinworth L, Holt DW, Sadiq ST: Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. J Antimicrob Chemother. 2010, 65: 2614-2619. 10.1093\/jac\/dkq369.","journal-title":"J Antimicrob Chemother"},{"key":"2468_CR46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR: \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975, 12: 189-198. 10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"key":"2468_CR47","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","volume":"69","author":"A Antinori","year":"2007","unstructured":"Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, et al: Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007, 69: 1789-1799. 10.1212\/01.WNL.0000287431.88658.8b.","journal-title":"Neurology"},{"key":"2468_CR48","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1097\/00002030-199910010-00011","volume":"13","author":"V Tozzi","year":"1999","unstructured":"Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D\u2019Amato C, Affricano C, Pigorini F, Pau FM, et al: Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS. 1999, 13: 1889-1897. 10.1097\/00002030-199910010-00011.","journal-title":"AIDS"},{"key":"2468_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/QAI.0b013e3181af83d6","volume":"52","author":"V Tozzi","year":"2009","unstructured":"Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A: Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr. 2009, 52: 56-63. 10.1097\/QAI.0b013e3181af83d6.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2468_CR50","doi-asserted-by":"crossref","unstructured":"Efavirenz (Sustiva). Res Initiat Treat Action. 2000, 6: 22-23.","DOI":"10.1159\/000055070"},{"key":"2468_CR51","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/jama.300.5.530","volume":"300","author":"A Boulle","year":"2008","unstructured":"Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G: Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA. 2008, 300: 530-539. 10.1001\/jama.300.5.530.","journal-title":"JAMA"},{"key":"2468_CR52","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1086\/599114","volume":"48","author":"W Manosuthi","year":"2009","unstructured":"Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, et al: A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis. 2009, 48: 1752-1759. 10.1086\/599114.","journal-title":"Clin Infect Dis"},{"key":"2468_CR53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/QAI.0b013e31819c33a3","volume":"50","author":"Y Ren","year":"2009","unstructured":"Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM: Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2009, 50: 439-443. 10.1097\/QAI.0b013e31819c33a3.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2468_CR54","volume-title":"AIDS","author":"H McIlleron","year":"2013","unstructured":"McIlleron H, Schomaker M, Ren Y, Sinxadi P, Nuttall JJ, Gous H, Moultrie H, Eley B, Merry M, Smith P, et al: Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS. 2013, 10.1097\/QAD.0b013e328360dbb4."},{"key":"2468_CR55","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00228-011-1166-5","volume":"68","author":"TN Gengiah","year":"2012","unstructured":"Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS: The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol. 2012, 68: 689-695. 10.1007\/s00228-011-1166-5.","journal-title":"Eur J Clin Pharmacol"},{"key":"2468_CR56","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/QAD.0b013e3283427e05","volume":"25","author":"A Kwara","year":"2011","unstructured":"Kwara A, Lartey M, Sagoe KW, Court MH: Paradoxically elevated efavirenz concentrations in HIV\/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS. 2011, 25: 388-390. 10.1097\/QAD.0b013e3283427e05.","journal-title":"AIDS"},{"key":"2468_CR57","volume-title":"Clin Infect Dis","author":"SL Rosenkranz","year":"2013","unstructured":"Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, et al: Relationship between weight, efavirenz exposure and virologic suppression in HIV-infected patients on rifampin-based TB treatment in the ACTG A5221 STRIDE study. Clin Infect Dis. 2013, 10.1093\/cid\/cit246. May 20. [Epub ahead of print]"},{"key":"2468_CR58","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3851\/IMP1780","volume":"16","author":"C Orrell","year":"2011","unstructured":"Orrell C, Cohen K, Conradie F, Zeinecker J, Ive P, Sanne I, Wood R: Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?. Antivir Ther. 2011, 16: 527-534. 10.3851\/IMP1780.","journal-title":"Antivir Ther"},{"key":"2468_CR59","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1183\/09031936.00159409","volume":"36","author":"N Guo","year":"2010","unstructured":"Guo N, Marra F, Fitzgerald JM, Elwood RK, Marra CA: Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis. Eur Respir J. 2010, 36: 206-208. 10.1183\/09031936.00159409.","journal-title":"Eur Respir J"},{"key":"2468_CR60","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1086\/655470","volume":"202","author":"HJ Ribaudo","year":"2010","unstructured":"Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, et al: Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2010, 202: 717-722. 10.1086\/655470.","journal-title":"J Infect Dis"},{"key":"2468_CR61","first-page":"2391","volume":"18","author":"DW Haas","year":"2004","unstructured":"Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004, 18: 2391-2400.","journal-title":"AIDS"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-13-261\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-13-261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T19:05:10Z","timestamp":1715454310000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-13-261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,4]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["2468"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-13-261","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,4]]},"assertion":[{"value":"28 November 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"261"}}